- Home
- IAE vs CTMX Comparison
IAE vs CTMX Comparison
Compare IAE & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAE
- CTMX
- Stock Information
- Founded
- IAE 2007
- CTMX 2008
- Country
- IAE United States
- CTMX United States
- Employees
- IAE N/A
- CTMX N/A
- Industry
- IAE Trusts Except Educational Religious and Charitable
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- IAE Finance
- CTMX Health Care
- Exchange
- IAE Nasdaq
- CTMX Nasdaq
- Market Cap
- IAE 68.1M
- CTMX 62.3M
- IPO Year
- IAE N/A
- CTMX 2015
- Fundamental
- Price
- IAE $6.35
- CTMX $0.78
- Analyst Decision
- IAE
- CTMX Buy
- Analyst Count
- IAE 0
- CTMX 6
- Target Price
- IAE N/A
- CTMX $5.77
- AVG Volume (30 Days)
- IAE 46.3K
- CTMX 688.7K
- Earning Date
- IAE 01-01-0001
- CTMX 03-10-2025
- Dividend Yield
- IAE 10.21%
- CTMX N/A
- EPS Growth
- IAE N/A
- CTMX N/A
- EPS
- IAE N/A
- CTMX 0.16
- Revenue
- IAE N/A
- CTMX $126,617,000.00
- Revenue This Year
- IAE N/A
- CTMX $22.55
- Revenue Next Year
- IAE N/A
- CTMX N/A
- P/E Ratio
- IAE N/A
- CTMX $4.83
- Revenue Growth
- IAE N/A
- CTMX 33.66
- 52 Week Low
- IAE $5.31
- CTMX $0.75
- 52 Week High
- IAE $6.45
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- IAE 63.88
- CTMX 40.63
- Support Level
- IAE $6.17
- CTMX $0.77
- Resistance Level
- IAE $6.33
- CTMX $0.83
- Average True Range (ATR)
- IAE 0.09
- CTMX 0.06
- MACD
- IAE 0.02
- CTMX 0.00
- Stochastic Oscillator
- IAE 75.06
- CTMX 13.04
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.